A race for the wealthy
- 01🧬 Biotech IPO Recovery Is Driven by M&A, Not Organic Momentum
- 02💰 Wealth Management Is the New Battleground for Capital and Consolidation
- 03⚡ Energy Transition Infrastructure Is Attracting Record Private Capital
- 04🤖 Physical AI Is Emerging as a High-Conviction Investment Category
- 05🛒 SaaS Valuations Are Creating a PE Buying Opportunity
1. Key Themes
🧬 Biotech IPO Recovery Is Driven by M&A, Not Organic Momentum
The article signals a tentative biotech IPO revival, but frames it as a downstream effect of aggressive big pharma acquisition activity rather than a standalone market recovery. Large deals are recycling capital back into the ecosystem and pulling pre-IPO companies toward public markets as a competitive negotiating tool.
"It's been a torrid pace linked to the patent cliff... Large pharmaceutical companies are anticipating many of their most profitable drugs will fall off patent in the coming years and are taking aggressive acquisitive strategies to backfill their pipelines." — Nimish Shah, Venrock Healthcare Capital Partners
"Later-stage biotech companies often explore going public while fielding acquisition offers... So a boom in M&A activity can raise the IPO interest from companies and investors." — Jessica Owens, Initiate Ventures
"Nineteen biopharma M&A deals of $1 billion or more were announced between January 1 and April 7 this year... putting the industry on pace to hit its second-highest total in history."
💰 Wealth Management Is the New Battleground for Capital and Consolidation
A furious M&A land grab is reshaping the wealth management industry, driven by the massive growth of the ultra-high-net-worth market. Asset managers, PE firms, broker-dealers, and fintechs are all competing to own wealthy client relationships, and the definition of "wealth management" itself is expanding.
"A furious land grab is underway as wealth advisers, alternatives firms, broker-dealers and fintech firms seek to capitalize on the growth of the ultra-high-net-worth market."
"What's new is you're seeing the definition of wealth management change over time... it's really moving to more of a holistic model, where it's not just financial planning and investment management, but you're expected to offer services that fall outside of that scope." — Barnaby Audsley, Echelon Partners
"The Carlyle Group recently agreed to become the majority owner of Cleveland-based registered investment adviser MAI Capital Management at a $2.8 billion valuation."
⚡ Energy Transition Infrastructure Is Attracting Record Private Capital
Despite political headwinds around ESG, infrastructure funds focused on the energy transition raised their largest-ever sum in 2025, signaling that institutional capital continues to flow into the space at scale regardless of rhetoric.
"Energy transition infrastructure funds raised their largest sum of capital ever in 2025, with generalist funds receiving $124.2 billion in commitments and specialist funds garnering $47.3 billion."
🤖 Physical AI Is Emerging as a High-Conviction Investment Category
The newsletter highlights a notable influx of talent, capital, and founder activity into "Physical AI" — robotics models that integrate visual perception, language understanding, and physical action — flagged by Andreessen Horowitz as a priority theme.
"Physical AI, including robotics models that combine visual perception, language understanding and physical action, is seeing an influx of talent, capital and founder activity." — Andreessen Horowitz
🛒 SaaS Valuations Are Creating a PE Buying Opportunity
Thoma Bravo's founder publicly characterized the current SaaS environment as an opportune moment for bargain hunting, suggesting that the prolonged "SaaS-pocalypse" has compressed valuations enough to attract aggressive buyout capital.
"The SaaS-pocalypse has created an opportune time for bargain hunting." — Orlando Bravo, Thoma Bravo
2. Contrarian Perspectives
Biotech's "Recovery" Is Structurally Narrow — Pre-Clinical Companies Remain Shut Out
The consensus narrative frames 2026 as a biotech comeback year. But the article punctures this: the IPO window is only open for large, late-stage companies, and performance among newly listed names is mostly poor. The 2020–2021 model of taking pre-clinical companies public is nowhere close to returning.
"More biopharma companies have gone public in 2026 at valuations of over $500 million than in all of 2025."
"Most of the newly listed biotech companies are underperforming industry benchmarks."
"What hasn't changed is that pre-clinical biopharma companies are still nowhere near going public as they did during the 2020 and 2021 IPO boom... biotech investors... are still facing FDA and supply chain uncertainty across their portfolios."
European VC Fundraising Headlines Mask a Deepening Quality Split
European VC fundraising looks healthy on the surface in Q1, but the underlying data tells a different story: a decade-high share of funds are closing below their predecessor sizes — a sign that capital is concentrating among winners while the broader manager base is shrinking.
"European VC fundraising was looking stronger in Q1, but a decade-high share of funds are closing below their predecessor sizes."
Allbirds' Pivot to AI Infrastructure Is a Cautionary (or Opportunistic) Signal
The shoemaker's pivot to AI infrastructure, resulting in a 500%+ stock jump, either signals how distorted AI sentiment has become — or that "AI infrastructure" as a label has become a powerful market signal independent of business fundamentals.
"Allbirds, known for its once-popular sneakers, stayed true to its Silicon Valley roots when it announced yesterday a pivot to AI infrastructure, with its stock price jumping by more than 500%."
3. Companies Identified
| Company | Description | Why Mentioned | Quote |
|---|---|---|---|
| Kailera Therapeutics | GLP-1 drug developer | Launched IPO roadshow at $1.9B valuation, exemplifying the large-cap biotech IPO recovery | "GLP-1 developer Kailera Therapeutics... launched IPO roadshows seeking valuations of $1.9 billion" |
| Alamar Biosciences | Proteomics company | Launched IPO roadshow at $1.1B valuation alongside Kailera | "Proteomics company Alamar Biosciences launched IPO roadshows seeking valuations of... $1.1 billion" |
| Terns Pharmaceuticals | Drug developer | Acquired by Merck for $6.7B — a flagship deal driving capital recycling in biotech | "Merck's $6.7 billion acquisition of Terns Pharmaceuticals" |
| Centessa Pharmaceuticals | Drug developer | Acquired by Eli Lilly for $6.3B upfront, illustrating patent cliff-driven M&A | "Eli Lilly's $6.3 billion upfront payment for Centessa Pharmaceuticals" |
| Enliven Therapeutics | Biotech | Named as a standout performer among newly public biotech companies | "Notable names, like Enliven Therapeutics and VeraDermics, have had a spectacular run in the past few months." |
| VeraDermics | Biotech | Named alongside Enliven as a rare IPO success story | "Notable names, like Enliven Therapeutics and VeraDermics, have had a spectacular run" |
| MAI Capital Management | Cleveland-based RIA | Carlyle's $2.8B majority acquisition illustrates wealth management land grab | "The Carlyle Group recently agreed to become the majority owner of... MAI Capital Management at a $2.8 billion valuation" |
| The Carlyle Group | Global PE/alt asset manager | Acquiring wealth management firm as part of broader alternatives expansion | "The Carlyle Group recently agreed to become the majority owner of... MAI Capital Management" |
| Terremoto Biosciences | Small molecule drug developer | Raised $108M Series C from top-tier healthcare investors | "Received a $108 million Series C from RA Capital Management, OrbiMed, Third Rock Ventures and others" |
| Hertha Metals | Low-carbon steel startup | Raising $100M Series A — signals continued industrial decarbonization investment | "A startup producing low-carbon steel, is raising $100 million in Series A funding" |
| Turion Space | Space-tech infrastructure company | Secured $75M Series B — space infrastructure continues to attract growth capital | "Secured a $75 million Series B led by Washington Harbour Partners" |
| HockeyStack | AI agents for enterprise | Raised $50M from Bessemer, YC, and Uncorrelated Ventures | "A startup developing AI agents for the enterprise, raised $50 million" |
| Helical | Virtual AI lab for pharma research | Seed-stage pharma AI company backed by Redalpine | "A Luxembourg-based virtual AI lab for pharma research, raised a $10 million seed investment" |
| SumUp | London-based payments startup | Lining up banks ahead of a potential IPO | "London-based payments startup SumUp is lining up banks ahead of a potential IPO" |
| Allbirds | Consumer shoe brand turned AI infrastructure | 500%+ stock spike on AI infrastructure pivot announcement | "Announced yesterday a pivot to AI infrastructure, with its stock price jumping by more than 500%" |
| LIV Golf | Professional golf events organizer backed by Saudi PIF | PIF considering cutting support after heavy financial losses | "Saudi Arabia's Public Investment Fund is considering cutting its support for golf events organizer LIV Golf after heavy financial losses" |
| Tory Burch | Luxury women's fashion retailer | Spending $346M to buy back General Atlantic's stake | "Will spend $346 million to repurchase General Atlantic's interest in the company" |
| eToro | Fintech trading specialist | Acquiring crypto wallet startup Zengo for $70M | "Is being purchased for $70 million by fintech trading specialist eToro" |
4. People Identified
| Person | Description | Why Mentioned | Quote |
|---|---|---|---|
| Orlando Bravo | Founder, Thoma Bravo | Called the current SaaS market an opportune time for bargain hunting at Semafor's World Economy Summit | "The SaaS-pocalypse has created an opportune time for bargain hunting" |
| Nimish Shah | Partner, Venrock Healthcare Capital Partners | Provided expert context on pharma patent cliff as the engine behind biopharma M&A and IPO activity | "It's been a torrid pace linked to the patent cliff" |
| Jessica Owens | Co-founder, Initiate Ventures | Explained the mechanic by which M&A activity elevates IPO interest among late-stage biotechs | "Later-stage biotech companies often explore going public while fielding acquisition offers" |
| Barnaby Audsley | Managing Director, Echelon Partners | Articulated the structural evolution of the wealth management business model toward holistic services | "It's really moving to more of a holistic model, where it's not just financial planning and investment management, but you're expected to offer services that fall outside of that scope" |
5. Operating Insights
Pre-IPO Biotech Founders: Use the M&A Boom to Create Competitive Tension
The current dynamic — where large pharma is aggressively acquiring to offset patent cliffs — creates real leverage for late-stage founders. Running an IPO process in parallel with M&A conversations is not just viable, it's strategic. The biotech IPO window is explicitly tied to M&A heat, not public market sentiment.
"Later-stage biotech companies often explore going public while fielding acquisition offers. So a boom in M&A activity can raise the IPO interest from companies and investors."
Founders: Fundraise Readiness Is a Competitive Advantage, Not a Formality
The newsletter's sponsored section (Fidelity Private Shares) surfaces a real operator truth: most fundraising failures are mechanical, not visionary. Having a clean cap table, reusable investor update templates, and organized diligence materials reduces friction and increases investor confidence at every stage.
"Most founders don't struggle with fundraising because of vision or ambition. They struggle because the mechanics are unclear, fragmented, and learned too late."
Wealth Management Firms Must Expand Beyond Core Services to Remain Competitive
For operators building or scaling wealth management businesses, the competitive moat is shifting from investment performance to breadth of holistic services. Firms that limit themselves to financial planning and investment management risk losing ground to those offering a broader lifestyle and financial services wrapper.
"It's really moving to more of a holistic model, where it's not just financial planning and investment management, but you're expected to offer services that fall outside of that scope."
6. Overlooked Insights
European VC Is Bifurcating at the Fund Level — A Decade-High Signal
The aggregate Q1 European VC fundraising figure looks encouraging, but the detail that a decade-high share of funds are closing below predecessor sizes is a significant structural warning. This suggests LPs are concentrating bets on proven managers while punishing underperformers — a dynamic that will accelerate manager attrition in European VC over the next cycle.
"European VC fundraising was looking stronger in Q1, but a decade-high share of funds are closing below their predecessor sizes."
Community Resistance to Data Centers Could Become a Meaningful Infrastructure Risk
Buried in the Side Letters section, a rural Maryland town pushing back on data center construction — citing "intolerable levels of noise" over tens of millions in tax revenue — is an early signal of local political friction that could complicate site acquisition, permitting timelines, and operating costs for data center developers and their investors at scale.
"A rural Maryland town is pushing for a pause on data center construction, fearing 'intolerable levels of noise' may not be worth the promise of tens of millions of dollars in fresh tax revenue."